259 related articles for article (PubMed ID: 25811972)
1. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.
Hou ZJ; Luo X; Zhang W; Peng F; Cui B; Wu SJ; Zheng FM; Xu J; Xu LZ; Long ZJ; Wang XT; Li GH; Wan XY; Yang YL; Liu Q
Oncotarget; 2015 Mar; 6(8):6326-40. PubMed ID: 25811972
[TBL] [Abstract][Full Text] [Related]
2. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
3. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
Ji P; Zhang Y; Wang SJ; Ge HL; Zhao GP; Xu YC; Wang Y
Oncol Rep; 2016 Jun; 35(6):3293-302. PubMed ID: 27109463
[TBL] [Abstract][Full Text] [Related]
4. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Li Y; Acharya G; Elahy M; Xin H; Khachigian LM
Cancer Lett; 2019 Sep; 459():268-276. PubMed ID: 31128215
[TBL] [Abstract][Full Text] [Related]
5. Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
Oh E; Kim YJ; An H; Sung D; Cho TM; Farrand L; Jang S; Seo JH; Kim JY
Int J Cancer; 2018 Oct; 143(8):1978-1993. PubMed ID: 29744876
[TBL] [Abstract][Full Text] [Related]
6. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
[TBL] [Abstract][Full Text] [Related]
7. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
An H; Kim JY; Lee N; Cho Y; Oh E; Seo JH
Biochem Biophys Res Commun; 2015 Oct; 466(4):696-703. PubMed ID: 26407842
[TBL] [Abstract][Full Text] [Related]
8. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy.
Lin S; Yang L; Yao Y; Xu L; Xiang Y; Zhao H; Wang L; Zuo Z; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jul; 38(1):293. PubMed ID: 31287013
[TBL] [Abstract][Full Text] [Related]
9. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
10. [Tricostantin A inhibits self-renewal of breast cancer stem cells in vitro].
Peng L; Li FX; Shao WF; Xiong JB
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1421-6. PubMed ID: 24144739
[TBL] [Abstract][Full Text] [Related]
11. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma.
Spagnuolo PA; Hu J; Hurren R; Wang X; Gronda M; Sukhai MA; Di Meo A; Boss J; Ashali I; Beheshti Zavareh R; Fine N; Simpson CD; Sharmeen S; Rottapel R; Schimmer AD
Blood; 2010 Jun; 115(23):4824-33. PubMed ID: 20348394
[TBL] [Abstract][Full Text] [Related]
12. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
13. Novel anticancer activity of phloroglucinol against breast cancer stem-like cells.
Kim RK; Uddin N; Hyun JW; Kim C; Suh Y; Lee SJ
Toxicol Appl Pharmacol; 2015 Aug; 286(3):143-50. PubMed ID: 25843036
[TBL] [Abstract][Full Text] [Related]
14. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
17. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
[TBL] [Abstract][Full Text] [Related]
18. Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent.
Khachigian LM
Cancer Lett; 2021 Dec; 522():57-62. PubMed ID: 34520820
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
